Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dainippon Sumitomo Prepares 2011 Schizophrenia Drug Launch In The U.S.

This article was originally published in PharmAsia News

Executive Summary

Major Japanese drug maker Dainippon Sumitomo will establish a holding company in the U.S. in July to prepare for an NDA submission to U.S. FDA for novel schizophrenia drug lurasidone (SM-13496). The company plans to submit the NDA for the antipsychotic agent with FDA in the first half of 2010, said President Masayo Tata, June 15. According to Dainippon Sumitomo, late-stage clinical trials for lurasidone resulted in promising results in confirming the drug's efficacy and safety, which prompted the company to move up the planned launch date in the U.S. from 2012 to 2011. (Click here for more - Japanese Language

You may also be interested in...

Lilly Signs Deals With Dexcom, Glooko, myDiabby, Roche For Diabetes Management Solutions

Lilly announced it signed strategic international agreements with four diabetes companies to advance connected solutions and streamline care for people with diabetes in markets outside of the US.

Three IPOs, Three SPAC Mergers, But One Company Opted Out

Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.

Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race

The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts